Latest Headlines

Latest Headlines

Bayer bracing for profit-margin drop

Bayer 's profit margins are dropping as a result of the European debt crisis. The German drug giant is responding as any cautious drug company would--by stocking up on cash, Reuters is reporting.

FDA panel wants label change for Yaz, Yasmin

An FDA advisory committee backed Bayer's ($BAY) birth control pills Yaz and Yasmin in a 15-11 vote yesterday, saying their benefits outweigh their risks. But the panel also recommended changes to the

Ampio to seek foreign OKs for premature ejaculation drug

Ampio Pharmaceuticals ($AMPE) is gearing up to seek international regulatory approval for its drug to treat premature ejaculation. The company disclosed Dec. 5 that it is preparing for this, in part,

Ex-FDA chief: Bayer held back Yasmin safety info

FDA reviewers are calling for more research on the safety of newer birth-control pills. The agency's expert panelists are gearing up to weigh evidence at a meeting later this week. Canadian

Fast-track for Eliquis puts Pradaxa, Xarelto on notice

Pradaxa and Xarelto may get heavyweight competition sooner than expected. The FDA has not only accepted Bristol-Myers Squibb ($BMY) and Pfizer's ($PFE) approval application for Eliquis, their new

Bayer emails discuss off-label uses for Yaz, Yasmin

Note to pharma marketing pros: Avoid using the word "off-label" in your emails. As Bloomberg reports, some messages discussing potential off-label promotions for the birth control pills Yaz and

Bayer chief aims for 37% pharma growth in China

Bayer CEO Marijn Dekkers (photo) likes to talk about his company's new anti-clotting drug Xarelto, and every time he mentions the brand, he seems more optimistic about it. He also likes to talk about

At AHA: Jury out on warfarin rivals, niacin needs to 'retire'

The onslaught of news from the American Heart Association's annual meeting continues. Major studies on Sanofi's Multaq and AstraZeneca's Crestor have made big headlines, but there are many more

J&J, Bayer can celebrate with ACS data on Xarelto

The big American Heart Association confab has begun, and already it has produced some big news. Data on Bayer and Johnson & Johnson's ($JNJ) Xarelto has doctors predicting a new standard of care

To pump up Prevenar, Pfizer looks to rural China

Like any country, China isn't one market, but many. Strategies for capturing share and growing sales in cities won't necessarily work in rural areas. And to grow as much as drugmakers want to in